LMR Partners LLP reduced its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 88.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 523,389 shares of the company's stock after selling 4,026,266 shares during the period. LMR Partners LLP's holdings in Kenvue were worth $12,106,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. ING Groep NV boosted its holdings in Kenvue by 23.6% in the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company's stock worth $82,727,000 after buying an additional 681,954 shares during the period. Lorne Steinberg Wealth Management Inc. boosted its holdings in Kenvue by 59.0% in the 2nd quarter. Lorne Steinberg Wealth Management Inc. now owns 154,690 shares of the company's stock worth $2,812,000 after buying an additional 57,375 shares during the period. Kennon Green & Company LLC boosted its holdings in Kenvue by 140.7% in the 2nd quarter. Kennon Green & Company LLC now owns 159,106 shares of the company's stock worth $2,893,000 after buying an additional 93,008 shares during the period. Czech National Bank boosted its holdings in Kenvue by 20.3% in the 2nd quarter. Czech National Bank now owns 364,886 shares of the company's stock worth $6,634,000 after buying an additional 61,635 shares during the period. Finally, Crestwood Advisors Group LLC lifted its stake in Kenvue by 14.8% in the 2nd quarter. Crestwood Advisors Group LLC now owns 1,537,348 shares of the company's stock worth $27,950,000 after purchasing an additional 198,607 shares in the last quarter. 97.64% of the stock is owned by institutional investors.
KVUE has been the topic of several research reports. Piper Sandler raised their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research report on Monday, September 23rd. Jefferies Financial Group assumed coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a "buy" rating and a $27.00 target price on the stock. UBS Group increased their target price on shares of Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. increased their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $22.64.
Get Our Latest Analysis on Kenvue
Shares of NYSE KVUE opened at $23.82 on Monday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.13. The stock has a market cap of $45.67 billion, a P/E ratio of 43.31, a price-to-earnings-growth ratio of 2.16 and a beta of 1.36. The firm has a 50-day moving average of $22.77 and a 200 day moving average of $20.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analysts' expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue's revenue was down .4% on a year-over-year basis. During the same period last year, the company posted $0.31 EPS. As a group, sell-side analysts expect that Kenvue Inc. will post 1.07 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.44%. Kenvue's dividend payout ratio (DPR) is presently 149.09%.
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.